Low-dose intralesional injection of 5-fluorouracil and triamcinolone reduces tissue resident memory T cells in chronic eczema

Table 1 Patient demographic and baseline disease characteristics

	Patients underwent randomization(n = 168)			Patients completed study(n = 161)
	5-FU + TA (n = 84)	TA (n = 84)	P	5-FU + TA (n = 80)	TA (n = 81)	P
Age (mean ± SD), yr	54.39 ± 14.31	56.12 ± 14.82	0.643	54.74 ± 14.26	55.60 ± 12.56	0.683
Range	28-74	28-79		28-74	29-79
28-45	36.17	38.48	0.120	36.27	38.16	0.236
46-60	53.48	53.41	0.962	53.50	53.41	0.950
61-	67.27	66	0.258	64.56	66.13	0.416
Sex, n (%)			0.739			0.774
Male	59 (70.24)	57 (67.86)		56 (70)	55 (67.90)
Female	25 (29.76)	27 (32.14)		24 (30)	26 (32.10)
Anatomical sites treated, n (%)
Trunk	23 (27.38)	22 (26.19)	0.862	23 (28.75)	22 (27.16)	0.822
Limb	58 (69.05)	61 (72.62)	0.611	54 (67.50)	58 (71.60)	0.571
Neck	3 (3.57)	1 (1.19)	0.613	3 (3.75)	1 (1.24)	0.604
ADSI score (mean ± SD)	7.72 ± 1	7.68 ± 1.02	0.468	7.71 ± 1	7.87 ± 0.90	0.278
Disease duration, yr (range)	4 (1-24)	4 (1-30)	0.944	3 (1-24)	3 (1-30)	0.925

FU: 5-fluorouracil; TA: triamcinolone; ADSI: atopic dermatitis severity index